Advertisement

Topics

Latest "Alnara Pharmaceuticals" News Stories

20:51 EDT 20th September 2018 | BioPortfolio

Here are the most relevant search results for "Alnara Pharmaceuticals" found in our extensive news archives from over 250 global news sources.

More Information about Alnara Pharmaceuticals on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Alnara Pharmaceuticals for you to read. Along with our medical data and news we also list Alnara Pharmaceuticals Clinical Trials, which are updated daily. BioPortfolio also has a large database of Alnara Pharmaceuticals Companies for you to search.

Showing "Alnara Pharmaceuticals" News Articles 1–25 of 10,000+

Thursday 20th September 2018

SCOUT and Rare Expertise Form Joint Venture to Help Identify and Treat People With Rare Diseases More Quickly and Accurately

Average 5-7 years for correct diagnosis impedes treatment, increases hospitalizations, takes heavy toll on patients and their families SCOUT, a leading healthcare marketing agency focused on orphan drugs and specialty pharmaceuticals, has formed a joint venture with Rare Expertise, a company with proprietary data-driven tools for identifying and activa...


KineMed Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12042018] Prices from USD $250

SummaryKineMed Inc KineMed is a biotechnology company that develops and commercializes proprietary biomarker platform technology. The company applies its proprietary biomarker platform technology to drug development, prescription, and nonprescription medical diagnostics and the pairing of drugs with diagnostic biomarker tests. It utilizes isotope labeling, mass spectrometry, and other techniques t...

InMed Pharmaceuticals (IN) - Progressing their programs

Edison Investment Research - Pharmaceutical & healthcare - InMed Pharmaceuticals: InMed continues to make progress on its biosynthesis platform, optimizing the genes that lead E. coli to express the cannabinoids and scaling up the fermentation process, both crucial steps needed to achieve commercial scale to address the market. InMed is also optimizing the formulation for INM-750 for epidermolysi...


Cardurion Pharmaceuticals Announces Initiation of Phase 1 Study of CRD-733, a PDE-9 Inhibitor in Development for the Treatment of Heart Failure

Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) for CRD-733, a Phosphodiesterase-9 (PDE-9) inhibitor in develop...

$CRBP Expands Target Indications, Adding ~600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery https://www.corbuspharma.com/news/press-releases/detail/282/corbus-pharmaceuticals-expands-target-indications-by-adding …

$CRBP Expands Target Indications, Adding ~600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery https://www.corbuspharma.com/news/press-releases/detail/282/corbus-pharmaceuticals-expands-target-indications-by-adding …

BioPlus Specialty Pharmacy Announces David DuRoss as Senior Vice President of Trade

BioPlus Specialty Pharmacy, one of the nation’s leading innovative specialty pharmacies, brings David DuRoss on board as the new Senior Vice President of Trade to meet growing needs of the company. ALTAMONTE SPRINGS, Fla. (PRWEB) September 20, 2018 BioPlus Specialty Pharmacy (BioPlus), one of the nation’s leading innovative specialty pharmacies, is pleased to announce that David DuRoss is joi...

Sunovion Receives Health Canada Approval of Aptiom

NewsAptiom provides an important new treatment option for adolescents and children above six years of age with partial-onset seizures. Contributed Author:&nb

Clinuvel Pharmaceuticals Aktie: Da kann man nicht meckern!

Die Zeiten von Kursexplosionen sind bei der Aktie von Clinuvel Pharmaceuticals wohl vorerst vorbei. Doch auch wenn die Aktie am Mittwoch um 0,8 Prozent abwertete, konnten Anleger sich darüber kaum ...

Vaxart Inc VXRT Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 14062018] Prices from USD $250

SummaryVaxart Inc Vaxart is a clinical stage biotechnology company which develops oral recombinant protein vaccines based on its proprietary oral vaccine delivery platform to treat infections. The company develops tablet vaccines for seasonal and pandemic influenza, norovirus, and respiratory syncytial virus RSV. Vaxart's vaccine delivery platform encompasses vectoradjuvant combination, which can ...

VIFOR PHARMA ANNOUNCES CHANGES IN MANAGEMENT

Vifor Pharma Ltd. / VIFOR PHARMA ANNOUNCES CHANGES IN MANAGEMENT . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. Barbara Angehrn joins Vifor Pharma as Chief Business Officer Patrick Treanor takes over from Scott Garland as President of Relypsa Vifor Pharma announced today changes to its manage...

Fibrocell Science Inc FCSC Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 16042018] Prices from USD $250

SummaryFibrocell Science Inc Fibrocell Science is an autologous cell and gene therapy company which discovers and develops therapies for diseases affecting the skin and connective tissue. The company's product pipeline comprises FCX007, a lead candidate for the treatment of recessive dystrophic epidermolysis bullosa; FCX013 for linear scleroderma; and a research program for the treatment of arthri...

Wednesday 19th September 2018

Pelago Bioscience AB Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 17042018] Prices from USD $250

SummaryPelago Bioscience AB Pelago Bioscience is a developer of patented cellular thermal shift assay for use in determination and quantification of drugtarget interactions. The company utilizes patented CETSA technology which enables direct, in situ physiologically relevant measurements of target engagement on target proteins in lysate, intact cells and tissue samples. Pelago Bioscience delivers ...

Celgene Walks Away from Licensing Deal with Beleaguered OncoMed

Shares of OncoMed Pharmaceuticals are falling this morning after the company announced that Celgene has walked away from a deal to license the company’s bispecific antibody navicixizumab.

Opiant Pharmaceuticals Announces Contract with Biomedical Advanced Research and Development Authority for Up to $4.6 Million to Accelerate Development of OPNT003, Nasal Nalmefene, for Treatment of Opioid Overdose

SANTA MONICA, Calif., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today announced that it has entered into a multi-year contract with potential funding up to a maximum of approximately $4.6 million, with the Biomedical Advanced Research and Development Au...

Tonix Pharmaceuticals to Present at Sidoti & Company Fall 2018 Investor Conference

NEW YORK, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present and host investor meetings at the Sidoti & Company Fall 2018 Investor Conference being held Thursday, September 27, 2018, in New York City. Details of the presentation are as follows: ...

Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease on September 25-27 in New York CityCantor Fitzgerald Global Healthcare Conference on October 1-3 in New York City CORAL GABLES, Fla., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for peopl...

Portola Pharmaceuticals Names Scott Garland President and Chief Executive Officer

– Relypsa president and former Exelixis chief commercial officer brings significant commercial and operational expertise – – Commercial responsibility for two of the industry’s most successful therapies, Avastin and Rituxan, during his tenure at Genentech –  SOUTH SAN FRANCISCO, Calif., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today annou...

Innovation Pharmaceuticals Provides Corporate Update Highlighting Upcoming Milestones and Events

BEVERLY, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide a corporate update on upcoming milestones and events across its clinical pipeline of first-in-class drug candidates, Brilacidin, Prurisol and Kevetrin. “Our clinical assets are both highly promising and well-diver...

AMAG Pharmaceuticals Partners With Emmy-Nominated Actress Cheryl Hines and Dr. Marla Shapiro to Start a Conversation About an Often Unrecognized and Untreated Medical Condition, Painful Sex Due to Menopause

WALTHAM, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that together with Emmy®-nominated actress Cheryl Hines and leading family medicine and menopause expert, Marla Shapiro, MD, it is launching an integrated campaign to start an open dialogue about painful sex due to menopause, a topic that is often not talked about among post-menopausal ...

Molecular Templates and Takeda to Take On Multiple Myeloma in Deal Worth up to $632 Million

Shares of Molecular Templates are up more than 52 percent in premarket trading after the company announced it has struck a deal with pharma giant Takeda Pharmaceuticals that could be worth up to $632 million to develop CD38-targeted engineered toxin bodies (ETBs).

Tetraphase Pharmaceuticals Announces Adoption of Commission Decision Granting Marketing Authorisation Approval in the European Union for XERAVA™ (eravacycline) for the Treatment of Complicated Intra-Abdominal Infections

– Broad Product Label for Treatment of Complicated Intra-Abdominal Infections – – Phased Commercial Launch Expected in the First Half of 2019 – WATERTOWN, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MD

Sotio AS Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 14062018] Prices from USD $250

SummarySotio AS Sotio, a subsidiary of PPF Group NV, is a biotechnology company that develops active cellular immunotherapy ACI based on activated dendritic cells. The company develops its product therapies using immunotherapy platform and proprietary cellbased technologies that are used for the treatment of cancer and autoimmune diseases. Sotio's research focuses on cancer immunotherapy and the a...

Shanghai Medicilon Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 14062018] Prices from USD $250

SummaryShanghai Medicilon Inc Medicilon is a drug discovery company that offers integrated services across biology, chemistry, preclinical and drug discovery processes. The company provides chemistry services such as medicinal chemistry, synthesis chemistry, process development and analytical chemistry. It offers drug formulation services such as preformulation development, analytical development,...

Deciphera Pharmaceuticals: Will This ASCO Winner Repeat At ESMO?

Aurinia to Participate in Upcoming Investor Conferences

Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and CEO, Richard Glickman, will present a company overview at two upcoming investor conferences. The presentations will be webcast live and can be accessed via the investor section of the Aurinia website, www.auriniapharma.com. A replay of each presentation will also...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks